US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TuHURA Biosciences, Inc.

1.96

+0.03001.55%

Post-market: 1.960.00000.00%16:10 EDT

Volume:148.97K

Turnover:292.59K

Market Cap:124.61M

PE:-3.61

High:1.99

Open:1.95

Low:1.95

Close:1.93

52wk High:3.43

52wk Low:0.4100

Shares:63.58M

Float Shares:39.66M

Volume Ratio:0.59

T/O Rate:0.38%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5428

EPS(LYR):-0.6272

ROE:-161.39%

ROA:-58.43%

PB:6.84

PE(LYR):-3.12

Loading ...

Overview Company News Filings

Press Release: TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Tuhura Biosciences Draws $650,000 from Parkview Revolving Credit Facility

TuHURA Biosciences Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview

Tuhura Biosciences Releases Corporate Deck Outlining Strategy to Tackle Cancer Immunotherapy Resistance

Tuhura Biosciences Draws $1.5 Million from Parkview Revolving Credit Facility

Tuhura Biosciences Draws $1.9 Million from Parkview Revolving Credit Facility

Tuhura Biosciences Announces Annual Shareholder Meeting Webcast

Tuhura Biosciences announces 2026 annual shareholder meeting

TuHURA Biosciences Files New Drug Application for Evaluation of Antibody to Treat Subsets of AML

MT Newswires Live

TuHURA Biosciences files FDA IND for TBS-2025 VISTA antibody in AML, blood cancers

Tuhura Biosciences - Targets Initiation of Phase 1B/2 Study in Second Half of 2026

THOMSON REUTERS

Tuhura Biosciences Files Investigational New Drug Application for Evaluation of the Tbs-2025 Vista Inhibiting Antibody in Molecularly Defined Subsets of Aml and Other Blood Related Cancers

THOMSON REUTERS

Tuhura Biosciences draws $1.7 million from Parkview $50 million credit facility

Tuhura Biosciences releases investor presentation on overcoming cancer immunotherapy resistance

Leverage, Covenants and Royalty Drain: Why Tuhura Biosciences’ Parkview Credit Deal Heightens Liquidity and Dilution Risks

TuHURA Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

TuHURA Biosciences Q1 EPS $(0.13) Misses $(0.12) Estimate

Benzinga Earnings

TuHURA Biosciences secures $50 million credit facility, royalty deal extends cash runway into 2028

Tuhura Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS

Press Release: TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/HURA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HURA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":1.96,"timestamp":1791576000000,"preClose":1.93,"halted":0,"volume":148973,"hourTrading":{"tag":"盘后","latestPrice":1.96,"preClose":1.96,"latestTime":"16:10 EDT","volume":4,"amount":7.84,"timestamp":1791576604050,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.015544041450777216,"floatShares":39657200,"shares":63578528,"eps":-0.542788,"marketStatus":"Post-Mkt","change":0.03,"latestTime":"10-09 17:46:16 EDT","open":1.95,"high":1.99,"low":1.95,"amount":292591,"amplitude":0.020725,"askPrice":2.09,"askSize":200,"bidPrice":1.87,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-0.542788,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791590400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.93,"postHourTrading":{"tag":"盘后","latestPrice":1.96,"preClose":1.96,"latestTime":"16:10 EDT","volume":4,"amount":7.84,"timestamp":1791576604050,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.590308},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","floatShares":39657200,"roa":"-58.43%","roe":"-161.39%","lyrEps":-0.627208,"volumeRatio":0.590308,"shares":63578528,"dividePrice":0,"high":1.99,"amplitude":0.020725,"preClose":1.93,"low":1.95,"week52Low":0.41,"pbRate":"6.84","week52High":3.43,"institutionHeld":0,"latestPrice":1.96,"committee":-0.6,"eps":-0.542788,"divideRate":0,"volume":148973,"delay":0,"ttmEps":-0.542788,"open":1.95,"prevYearClose":0.7567,"prevWeekClose":1.91,"prevMonthClose":2.1,"prevQuarterClose":2.1,"fiveDayClose":1.91,"twentyDayClose":2.05,"sixtyDayClose":2.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HURA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"HURA","fiscalQuarterEnding":"2026/06","expectedEps":-0.15,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2026-05-15","symbol":"HURA","fiscalQuarterEnding":"2026/03","expectedEps":-0.11,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2026-03-31","symbol":"HURA","fiscalQuarterEnding":"2025/12","expectedEps":-0.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2025-11-14","symbol":"HURA","fiscalQuarterEnding":"2025/09","expectedEps":-0.15,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-08-14","symbol":"HURA","fiscalQuarterEnding":"2025/06","expectedEps":-0.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.21}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HURA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HURA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1777348800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HURA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HURA","date":"2026-10-08","current":-3.610986,"percent":0.787629,"low":-15.284879,"twenty":-7.555364,"median":-4.726116,"eighty":-4.055939,"high":-0.912265,"avg":-5.445139,"sd":2.599691,"marketCap":126178701},"quantilePoints":[{"date":"2024-10-31","current":-8.730961,"twenty":-7.999797,"median":-7.383325,"eighty":-6.996296,"marketCap":255964076},{"date":"2024-11-08","current":-7.555364,"twenty":-8.206244,"median":-7.555364,"eighty":-7.208419,"marketCap":221499291},{"date":"2024-11-15","current":-7.024911,"twenty":-7.675791,"median":-7.239959,"eighty":-7.070789,"marketCap":205948107},{"date":"2024-11-22","current":-7.665321,"twenty":-7.599347,"median":-7.225623,"eighty":-6.910219,"marketCap":140801257},{"date":"2024-11-29","current":-15.010301,"twenty":-7.933971,"median":-7.512354,"eighty":-7.036381,"marketCap":275718282},{"date":"2024-12-06","current":-13.866223,"twenty":-11.098214,"median":-7.555364,"eighty":-7.065054,"marketCap":254703169},{"date":"2024-12-13","current":-12.310277,"twenty":-13.486389,"median":-7.688203,"eighty":-7.082258,"marketCap":226122615},{"date":"2024-12-20","current":-9.152622,"twenty":-13.106555,"median":-8.294564,"eighty":-7.105196,"marketCap":168120904},{"date":"2024-12-27","current":-10.411108,"twenty":-12.712992,"median":-8.730961,"eighty":-7.156808,"marketCap":191237528},{"date":"2025-01-03","current":-9.404319,"twenty":-12.676382,"median":-9.175503,"eighty":-7.225623,"marketCap":172744228},{"date":"2025-01-10","current":-9.541609,"twenty":-12.383498,"median":-9.381438,"eighty":-7.248561,"marketCap":175266042},{"date":"2025-01-17","current":-10.822976,"twenty":-11.486541,"median":-9.518727,"eighty":-7.460742,"marketCap":198802968},{"date":"2025-01-24","current":-10.571279,"twenty":-11.170776,"median":-9.724661,"eighty":-7.521761,"marketCap":194179644},{"date":"2025-01-31","current":-11.325839,"twenty":-11.2987,"median":-9.861951,"eighty":-7.544431,"marketCap":208039858},{"date":"2025-02-07","current":-10.266919,"twenty":-11.2987,"median":-10.022121,"eighty":-7.555364,"marketCap":188588977},{"date":"2025-02-14","current":-10.552406,"twenty":-11.252498,"median":-10.136529,"eighty":-7.621338,"marketCap":193832969},{"date":"2025-02-21","current":-7.603262,"twenty":-11.206135,"median":-9.999239,"eighty":-7.574523,"marketCap":139661309},{"date":"2025-02-28","current":-5.806127,"twenty":-11.137841,"median":-9.861951,"eighty":-7.518625,"marketCap":106650454},{"date":"2025-03-07","current":-4.700198,"twenty":-11.042639,"median":-9.689249,"eighty":-7.174012,"marketCap":86336082},{"date":"2025-03-14","current":-4.561957,"twenty":-10.951113,"median":-9.541609,"eighty":-7.036381,"marketCap":83796785},{"date":"2025-03-21","current":-9.216075,"twenty":-10.928231,"median":-9.438641,"eighty":-6.704264,"marketCap":169286436},{"date":"2025-03-28","current":-8.340548,"twenty":-10.90535,"median":-9.216075,"eighty":-6.852872,"marketCap":153204224},{"date":"2025-04-04","current":-6.636447,"twenty":-10.864163,"median":-9.011547,"eighty":-6.704264,"marketCap":143893470},{"date":"2025-04-11","current":-7.796363,"twenty":-10.722297,"median":-8.730961,"eighty":-6.759947,"marketCap":169043136},{"date":"2025-04-17","current":-8.340296,"twenty":-10.567504,"median":-8.501461,"eighty":-6.795924,"marketCap":180836843},{"date":"2025-04-25","current":-8.521606,"twenty":-10.542452,"median":-8.46117,"eighty":-6.852364,"marketCap":184768079},{"date":"2025-05-02","current":-7.8568,"twenty":-10.498764,"median":-8.409668,"eighty":-7.030646,"marketCap":170353548},{"date":"2025-05-09","current":-7.917237,"twenty":-10.46885,"median":-8.350494,"eighty":-7.05932,"marketCap":171663960},{"date":"2025-05-16","current":-7.735926,"twenty":-10.401955,"median":-8.271427,"eighty":-7.082258,"marketCap":167732724},{"date":"2025-05-23","current":-5.593729,"twenty":-10.356677,"median":-8.259713,"eighty":-7.009861,"marketCap":131477994},{"date":"2025-05-30","current":-5.909654,"twenty":-10.322004,"median":-8.210864,"eighty":-6.792598,"marketCap":138903659},{"date":"2025-06-06","current":-5.370723,"twenty":-10.312959,"median":-8.038111,"eighty":-6.609295,"marketCap":126236344},{"date":"2025-06-13","current":-4.86896,"twenty":-10.273819,"median":-7.961523,"eighty":-5.965405,"marketCap":114442640},{"date":"2025-06-20","current":-5.01763,"twenty":-10.268299,"median":-7.907165,"eighty":-5.77585,"marketCap":117937071},{"date":"2025-06-27","current":-4.255694,"twenty":-10.254133,"median":-7.8568,"eighty":-5.590128,"marketCap":100028109},{"date":"2025-07-03","current":-4.911411,"twenty":-10.238281,"median":-7.856432,"eighty":-5.456208,"marketCap":115440443},{"date":"2025-07-11","current":-4.990628,"twenty":-10.201312,"median":-7.766145,"eighty":-5.256797,"marketCap":117302386},{"date":"2025-07-18","current":-5.010432,"twenty":-10.182292,"median":-7.688203,"eighty":-5.039996,"marketCap":117767871},{"date":"2025-07-25","current":-5.624358,"twenty":-10.127376,"median":-7.668851,"eighty":-5.052895,"marketCap":132197927},{"date":"2025-08-01","current":-4.911411,"twenty":-10.049579,"median":-7.615053,"eighty":-5.052895,"marketCap":115440443},{"date":"2025-08-08","current":-4.812391,"twenty":-9.994663,"median":-7.555364,"eighty":-5.037142,"marketCap":113113015},{"date":"2025-08-15","current":-4.975285,"twenty":-9.907714,"median":-7.528032,"eighty":-5.017728,"marketCap":138129515},{"date":"2025-08-22","current":-5.245681,"twenty":-9.861951,"median":-7.477167,"eighty":-5.037142,"marketCap":145636554},{"date":"2025-08-29","current":-5.065417,"twenty":-9.847676,"median":-7.326779,"eighty":-5.052895,"marketCap":140631862},{"date":"2025-09-05","current":-4.560678,"twenty":-9.79276,"median":-7.254296,"eighty":-5.013311,"marketCap":126618722},{"date":"2025-09-12","current":-4.668836,"twenty":-9.696332,"median":-7.110931,"eighty":-4.956091,"marketCap":129621538},{"date":"2025-09-19","current":-4.65081,"twenty":-9.618099,"median":-7.053585,"eighty":-4.911411,"marketCap":129121069},{"date":"2025-09-26","current":-4.416467,"twenty":-9.555338,"median":-6.959639,"eighty":-4.875184,"marketCap":122614968},{"date":"2025-10-03","current":-4.704889,"twenty":-9.532456,"median":-6.792598,"eighty":-4.824615,"marketCap":130622476},{"date":"2025-10-10","current":-4.65081,"twenty":-9.500422,"median":-6.659051,"eighty":-4.759515,"marketCap":129121069},{"date":"2025-10-17","current":-4.326335,"twenty":-9.445506,"median":-6.451252,"eighty":-4.704889,"marketCap":120112622},{"date":"2025-10-24","current":-4.019886,"twenty":-9.386014,"median":-6.151486,"eighty":-4.692197,"marketCap":111604644},{"date":"2025-10-31","current":-4.470546,"twenty":-9.301564,"median":-5.965405,"eighty":-4.668836,"marketCap":124116376},{"date":"2025-11-07","current":-4.416467,"twenty":-9.208999,"median":-5.850391,"eighty":-4.621968,"marketCap":122614968},{"date":"2025-11-14","current":-3.677385,"twenty":-9.18008,"median":-5.798151,"eighty":-4.596731,"marketCap":102095729},{"date":"2025-11-21","current":-2.774116,"twenty":-9.039762,"median":-5.662432,"eighty":-4.565822,"marketCap":81244064},{"date":"2025-11-28","current":-3.500461,"twenty":-8.84257,"median":-5.63426,"eighty":-4.556086,"marketCap":102516170},{"date":"2025-12-05","current":-3.465457,"twenty":-8.730961,"median":-5.593729,"eighty":-4.544729,"marketCap":101491008},{"date":"2025-12-12","current":-1.811489,"twenty":-8.705462,"median":-5.561421,"eighty":-4.506599,"marketCap":53052117},{"date":"2025-12-19","current":-1.552105,"twenty":-8.587093,"median":-5.505534,"eighty":-4.470546,"marketCap":45455669},{"date":"2025-12-26","current":-1.707387,"twenty":-8.521606,"median":-5.445058,"eighty":-4.45252,"marketCap":50003338},{"date":"2026-01-02","current":-1.568888,"twenty":-8.50549,"median":-5.407919,"eighty":-4.416467,"marketCap":45947208},{"date":"2026-01-09","current":-1.564327,"twenty":-8.469228,"median":-5.371294,"eighty":-4.409256,"marketCap":45813623},{"date":"2026-01-16","current":-1.57656,"twenty":-8.46117,"median":-5.317787,"eighty":-4.331172,"marketCap":46171874},{"date":"2026-01-23","current":-1.408413,"twenty":-8.46117,"median":-5.267885,"eighty":-4.319125,"marketCap":41247441},{"date":"2026-01-30","current":-1.163138,"twenty":-8.430269,"median":-5.249422,"eighty":-4.265631,"marketCap":34064204},{"date":"2026-02-06","current":-0.912265,"twenty":-8.395844,"median":-5.227655,"eighty":-4.145319,"marketCap":26717023},{"date":"2026-02-13","current":-2.881928,"twenty":-8.370916,"median":-5.188669,"eighty":-4.09774,"marketCap":84401506},{"date":"2026-02-20","current":-2.301396,"twenty":-8.352484,"median":-5.119354,"eighty":-3.87886,"marketCap":67399763},{"date":"2026-02-27","current":-3.358794,"twenty":-8.340447,"median":-5.054798,"eighty":-3.490101,"marketCap":98367222},{"date":"2026-03-06","current":-3.234394,"twenty":-8.312748,"median":-5.017712,"eighty":-3.42514,"marketCap":94723992},{"date":"2026-03-13","current":-4.063726,"twenty":-8.270771,"median":-4.990628,"eighty":-3.42514,"marketCap":119012195},{"date":"2026-03-20","current":-3.71126,"twenty":-8.265757,"median":-4.95929,"eighty":-3.463659,"marketCap":108689709},{"date":"2026-03-27","current":-4.042992,"twenty":-8.259713,"median":-4.911411,"eighty":-3.465457,"marketCap":118404990},{"date":"2026-04-02","current":-3.427302,"twenty":-8.251655,"median":-4.911411,"eighty":-3.465457,"marketCap":102997215},{"date":"2026-04-10","current":-4.146613,"twenty":-8.215999,"median":-4.888063,"eighty":-3.434334,"marketCap":124613914},{"date":"2026-04-17","current":-6.262232,"twenty":-8.188482,"median":-4.911411,"eighty":-3.463059,"marketCap":188192442},{"date":"2026-04-24","current":-4.844767,"twenty":-8.114171,"median":-4.911411,"eighty":-3.465457,"marketCap":145594829},{"date":"2026-05-01","current":-4.738986,"twenty":-8.030053,"median":-4.911411,"eighty":-3.469004,"marketCap":142415902},{"date":"2026-05-08","current":-5.077485,"twenty":-7.995389,"median":-4.911411,"eighty":-3.486647,"marketCap":152588467},{"date":"2026-05-15","current":-5.310203,"twenty":-7.976007,"median":-4.911411,"eighty":-3.500461,"marketCap":159582105},{"date":"2026-05-22","current":-4.818786,"twenty":-7.933354,"median":-4.916581,"eighty":-3.501154,"marketCap":149017115},{"date":"2026-05-29","current":-4.839379,"twenty":-7.917237,"median":-4.916581,"eighty":-3.503927,"marketCap":149653940},{"date":"2026-06-05","current":-4.509889,"twenty":-7.897092,"median":-4.911411,"eighty":-3.58686,"marketCap":139464736},{"date":"2026-06-12","current":-4.509889,"twenty":-7.897092,"median":-4.904697,"eighty":-3.677385,"marketCap":139464736},{"date":"2026-06-18","current":-4.571669,"twenty":-7.864858,"median":-4.888063,"eighty":-3.704485,"marketCap":141375212},{"date":"2026-06-26","current":-5.333613,"twenty":-7.8568,"median":-4.908236,"eighty":-3.727846,"marketCap":164937747},{"date":"2026-07-02","current":-5.04531,"twenty":-7.856579,"median":-4.901158,"eighty":-3.744433,"marketCap":156022193},{"date":"2026-07-10","current":-4.818786,"twenty":-7.844566,"median":-4.888063,"eighty":-3.771996,"marketCap":149017115},{"date":"2026-07-17","current":-4.571669,"twenty":-7.81248,"median":-4.891607,"eighty":-3.786112,"marketCap":141375212},{"date":"2026-07-24","current":-4.427517,"twenty":-7.760101,"median":-4.868044,"eighty":-3.812345,"marketCap":136917435},{"date":"2026-07-31","current":-4.468703,"twenty":-7.71981,"median":-4.860726,"eighty":-3.856706,"marketCap":138191085},{"date":"2026-08-07","current":-4.355441,"twenty":-7.692662,"median":-4.839379,"eighty":-3.914446,"marketCap":134688546},{"date":"2026-08-14","current":-4.736413,"twenty":-7.681875,"median":-4.818786,"eighty":-3.97155,"marketCap":146469814},{"date":"2026-08-21","current":-4.616534,"twenty":-7.672382,"median":-4.818786,"eighty":-4.019886,"marketCap":141375212},{"date":"2026-08-28","current":-4.432444,"twenty":-7.669558,"median":-4.813895,"eighty":-4.020835,"marketCap":135737694},{"date":"2026-09-04","current":-4.370015,"twenty":-7.66133,"median":-4.7776,"eighty":-4.030552,"marketCap":133825895},{"date":"2026-09-11","current":-4.224348,"twenty":-7.647286,"median":-4.769319,"eighty":-4.043702,"marketCap":129365032},{"date":"2026-09-18","current":-4.349206,"twenty":-7.612695,"median":-4.752979,"eighty":-4.048423,"marketCap":133188629},{"date":"2026-09-25","current":-4.370015,"twenty":-7.593682,"median":-4.741306,"eighty":-4.057496,"marketCap":133825895},{"date":"2026-10-02","current":-4.1203,"twenty":-7.555364,"median":-4.737643,"eighty":-4.067873,"marketCap":126178701},{"date":"2026-10-08","current":-4.1203,"twenty":-7.555364,"median":-4.726116,"eighty":-4.055939,"marketCap":126178701}],"updateTime":1791582375110},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HURA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659616146","title":"Press Release: TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659616146","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659616146?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:45","pubTimestamp":1786707900,"startTime":"0","endTime":"0","summary":"TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended June 30, 2026, and provided a corporate update.\"We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year,\" said Dr. James Bianco, President and CEO of TuHURA Biosciences. \"In the second half, we anticipate receiving safe-to-proceed feedback from FDA and to initiating our Phase 1b/2 trial of VISTA in mutNPM1 r/r AML, initiating our in vivo POC studies for MDSC Inhibitors , potentially receiving orphan drug designation in Merkel cell carcinoma  for IFx-2.0, and potentially receiving orphan drug designation in AML for TBS-2025. The recent $50 million term credit facility made available to us by our largest ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","R","HURA","BK4232","BK4022","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659160230","title":"Tuhura Biosciences Draws $650,000 from Parkview Revolving Credit Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2659160230","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659160230?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:01","pubTimestamp":1786654906,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences draws $650,000 from Parkview revolving credit facilityTuhura Biosciences drew USD 650,000 under its revolving credit facility with Parkview Holdings One on Aug. 7, 2026.The revolvin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL9DjWp2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659880900","title":"TuHURA Biosciences Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2659880900","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659880900?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:11","pubTimestamp":1786565480,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc <HURA.OQ> expected to post a loss of14cents a share - Earnings PreviewTuHURA Biosciences IncHURA.OQHURA.Ois expected to  show no change in quarterly revenue when it reports  res","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N449236:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658179749","title":"Tuhura Biosciences Releases Corporate Deck Outlining Strategy to Tackle Cancer Immunotherapy Resistance","url":"https://stock-news.laohu8.com/highlight/detail?id=2658179749","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658179749?lang=en_us&edition=fundamental","pubTime":"2026-08-12 02:16","pubTimestamp":1786472170,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences releases corporate deck outlining strategy to tackle cancer immunotherapy resistanceTuhura Biosciences highlighted a Phase 3 accelerated-approval study of IFx-2.0 with pembrolizumab","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL49LLSc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655689812","title":"Tuhura Biosciences Draws $1.5 Million from Parkview Revolving Credit Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2655689812","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655689812?lang=en_us&edition=fundamental","pubTime":"2026-07-30 05:22","pubTimestamp":1785360145,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences draws $1.5 million from Parkview revolving credit facilityTuhura Biosciences drew USD 1.5 million under its revolving credit facility with Parkview Holdings One.The credit facility,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL9v3gVN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649958134","title":"Tuhura Biosciences Draws $1.9 Million from Parkview Revolving Credit Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2649958134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649958134?lang=en_us&edition=fundamental","pubTime":"2026-07-08 05:31","pubTimestamp":1783459867,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences draws $1.9 million from Parkview revolving credit facilityTuHURA Biosciences drew USD 1.9 million on June 30, 2026 under a revolving credit facility with Parkview Holdings One.The f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL3fkRhB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646393380","title":"Tuhura Biosciences Announces Annual Shareholder Meeting Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2646393380","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646393380?lang=en_us&edition=fundamental","pubTime":"2026-06-27 05:27","pubTimestamp":1782509261,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences announces annual shareholder meeting webcastTuHURA Biosciences will hold its annual shareholder meeting via virtual webcast on Aug. 18, 2026.Shareholders will vote on electing six d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDLSM4KF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644721629","title":"Tuhura Biosciences announces 2026 annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2644721629","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644721629?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:31","pubTimestamp":1781728274,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences will hold its 2026 annual meeting virtually on Aug. 18, 2026.The company set June 27, 2026 as the deadline for shareholders to submit proposals for inclusion in meeting materials.June 27, 2026 is also the cutoff for proxy access director nominations or other shareholder proposals and director nominations submitted under the bylaws.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDLWx0m0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643321205","title":"TuHURA Biosciences Files New Drug Application for Evaluation of Antibody to Treat Subsets of AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2643321205","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643321205?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:33","pubTimestamp":1781526828,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences  said Monday it has filed an investigational new drug application with the US Food and Drug Administration for a study evaluating its TBS-2025 VISTA inhibiting antibody to treat molecularly defined subsets of acute myeloid leukemia and other blood-related cancers.The company said the application is being filed following detailed feedback and guidance from the FDA on the previous IND filed in February.The company said it is targeting starting the phase 1b/2 study in the second half of this year, depending on the FDA's written responses expected next month.Shares of the company were up 3% in Monday's premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643084712","title":"TuHURA Biosciences files FDA IND for TBS-2025 VISTA antibody in AML, blood cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2643084712","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643084712?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:49","pubTimestamp":1781524186,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences filed an IND with the FDA for TBS-2025, a VISTA-inhibiting antibody, in molecularly defined AML subsets.The FDA declined a requested meeting, opting to provide written feedback on the proposed Phase 1b/2 AML plan next month.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL8zGByq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643208444","title":"Tuhura Biosciences - Targets Initiation of Phase 1B/2 Study in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643208444","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643208444?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:49","pubTimestamp":1781524166,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA4FLRVQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643084422","title":"Tuhura Biosciences Files Investigational New Drug Application for Evaluation of the Tbs-2025 Vista Inhibiting Antibody in Molecularly Defined Subsets of Aml and Other Blood Related Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2643084422","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643084422?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:49","pubTimestamp":1781524166,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA4FLRVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639677746","title":"Tuhura Biosciences draws $1.7 million from Parkview $50 million credit facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2639677746","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639677746?lang=en_us&edition=fundamental","pubTime":"2026-05-30 05:01","pubTimestamp":1780088472,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences entered a loan agreement with Parkview Holdings One for a revolving credit facility with up to $50 million of availability.Tuhura drew $1.7 million on May 26, 2026, marking the first borrowing under the facility.Proceeds are expected to fund general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL8F5glm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636200888","title":"Tuhura Biosciences releases investor presentation on overcoming cancer immunotherapy resistance","url":"https://stock-news.laohu8.com/highlight/detail?id=2636200888","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636200888?lang=en_us&edition=fundamental","pubTime":"2026-05-19 09:07","pubTimestamp":1779152849,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences outlined a $50 million non-equity credit facility and royalty transaction, projecting cash runway through Q1 2028.Facility terms include 5 years of interest-only payments at 12% on drawn amounts, a 10% commitment fee payable in shares at $2.66 subject to shareholder approval, a 1.5% annual cash fee.Royalty applies only to IFx-2.0 sales, described as low- to mid-single digits up to $450 million in annual sales.Pipeline updates include a VISTA-inhibiting antibody program in AML with a Phase 1b/2 start targeted for 2H 2026, alongside immune-modulating ADC proof-of-concept work with data targeted for 2H 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to gen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDLPVVz9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636258096","title":"Leverage, Covenants and Royalty Drain: Why Tuhura Biosciences’ Parkview Credit Deal Heightens Liquidity and Dilution Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2636258096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636258096?lang=en_us&edition=fundamental","pubTime":"2026-05-17 14:01","pubTimestamp":1778997704,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences, Inc. (HURA) has disclosed a new risk, in the Debt & Financing category. The analyst notes that Tuhura Biosciences, Inc.’s revol...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/leverage-covenants-and-royalty-drain-why-tuhura-biosciences-parkview-credit-deal-heightens-liquidity-and-dilution-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/leverage-covenants-and-royalty-drain-why-tuhura-biosciences-parkview-credit-deal-heightens-liquidity-and-dilution-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635536055","title":"TuHURA Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635536055","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635536055?lang=en_us&edition=fundamental","pubTime":"2026-05-16 06:33","pubTimestamp":1778884390,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc reports results for the quarter ended March 31 - Earnings SummaryTuHURA Biosciences Inc HURA.OQ reported a quarterly adjusted loss of 13 cents per share for the quarter ended Ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S29T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635533940","title":"TuHURA Biosciences Q1 EPS $(0.13) Misses $(0.12) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635533940","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635533940?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:27","pubTimestamp":1778880435,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 13.33 percent increase over losses of $(0.15) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52619494/tuhura-biosciences-q1-eps-0-13-misses-0-12-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"TuHURA Biosciences Q1 EPS $(0.13) Misses $(0.12) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635058161","title":"TuHURA Biosciences secures $50 million credit facility, royalty deal extends cash runway into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2635058161","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635058161?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:01","pubTimestamp":1778878871,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences entered a $50 million credit facility and royalty transaction in April 2026, extending anticipated cash runway into 2028.Facility allows drawdowns as needed to fund monthly operating expenses tied to clinical development and operations.Borrowings carry 12% annual interest on drawn amounts, paid monthly.Principal repayment due at 5-year maturity on April 21, 2031.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL9Md7Wj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635920058","title":"Tuhura Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635920058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635920058?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:00","pubTimestamp":1778878802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA114WDZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635058439","title":"Press Release: TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635058439","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635058439?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:00","pubTimestamp":1778878800,"startTime":"0","endTime":"0","summary":"TAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's first quarter ended March 31, 2026, and provided a corporate update.\"I am very pleased with the progress we have made this past quarter as we continue to execute upon our corporate and development strategy. Importantly, we recently established a $50 million non-equity-based source of operating capital in the form of credit facility with our largest stockholder on attractive terms for the company allowing us to fund operations beyond anticipated top-line data in our lead IFx-2.0 program,\" said Dr. James Bianco, President and CEO of TuHURA Biosciences. \"With the financing optionality provided by the credit facility, we now look forward to several anticipated key upcoming milestones, including: meeting with the FDA to discuss our IND and development plan for o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4139","IE0009354923.USD","ODD","BK4232","HURA","R","BK4022"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":53,"code":"91000000","status":"200"}]}}